Why Amylyx is pulling ALS drug Relyvrio from US market after study
Time:2024-05-21 08:03:10 Source:styleViews(143)
WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with the deadly neurological condition.
Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription.
“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS,” company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free.
The Food and Drug Administration approved the much-debated drug, Relyvrio, in September 2022, following a years-long advocacy campaign by patients with amyotrophic lateral sclerosis, or ALS.
Previous:'Constantly learning' Imanaga off to impressive start with the Chicago Cubs
Next:Minnesota Uber and Lyft driver pay package beats deadline to win approval in Legislature
You may also like
- Minnesota Uber and Lyft driver pay package beats deadline to win approval in Legislature
- The Masters updates: Tiger Woods set out to make more history
- Maryland program to help Port of Baltimore businesses retain employees begins
- Benteler Steel plans $21 million expansion, will create 49 jobs
- Socialite Jasmine Hartin enjoys beach snuggle with electrician hunk
- Transitional council in Haiti to choose new leaders is formally established amid gang violence
- Manuel Rocha, a former US ambassador, sentenced to 15 years for serving as secret agent for Cuba
- Kansas governor vetoes ban on gender
- Sweden beats France, Britain relegated after losing to Norway at hockey worlds